Author: Arabi, Yaseen M.; Asiri, Ayed Y.; Assiri, Abdullah M.; Aziz Jokhdar, Hani A.; Alothman, Adel; Balkhy, Hanan H.; AlJohani, Sameera; Al Harbi, Shmeylan; Kojan, Suleiman; Al Jeraisy, Majed; Deeb, Ahmad M.; Memish, Ziad A.; Ghazal, Sameeh; Al Faraj, Sarah; Al-Hameed, Fahad; AlSaedi, Asim; Mandourah, Yasser; Al Mekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; Almotairi, Abdullah; Al Bshabshe, Ali; Kharaba, Ayman; Jose, Jesna; Al Harthy, Abdulrahman; Al Sulaiman, Mohammed; Mady, Ahmed; Fowler, Robert A.; Hayden, Frederick G.; Al-Dawood, Abdulaziz; Abdelzaher, Mohamed; Bajhmom, Wail; Hussein, Mohamed A.
Title: Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial Cord-id: 0cah15lg Document date: 2020_1_3
ID: 0cah15lg
Snippet: ABSTRACT: The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-bli
Document: ABSTRACT: The MIRACLE trial (MERS-CoV Infection tReated with A Combination of Lopinavir/ritonavir and intErferon-β1b) investigates the efficacy of a combination therapy of lopinavir/ritonavir and recombinant interferon-β1b provided with standard supportive care, compared to placebo provided with standard supportive care, in hospitalized patients with laboratory-confirmed MERS. The MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The aim of this article is to describe the statistical analysis plan for the MIRACLE trial. The primary outcome is 90-day mortality. The primary analysis will follow the intention-to-treat principle. The MIRACLE trial is the first randomized controlled trial for MERS treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02845843. Registered on 27 July 2016.
Search related documents:
Co phrase search for related documents- absolute risk reduction and logistic regression: 1, 2
- absolute risk reduction and logistic regression analysis: 1
- absolute risk reduction and lopinavir ritonavir: 1, 2, 3
- acute pancreatitis and adjust analysis: 1
- acute pancreatitis and logistic regression: 1, 2, 3, 4
- acute pancreatitis and logistic regression analysis: 1, 2, 3
- acute pancreatitis and lopinavir ritonavir: 1, 2
- acute pancreatitis and lymphocyte count: 1, 2, 3, 4
- adaptive trial and additional file: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive trial and adequate planning: 1
- adaptive trial and logistic regression: 1, 2
- adaptive trial and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
- additional file and logistic regression: 1
- additional file and logistic regression analysis: 1
- additional file and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- additional file and lymphocyte count: 1, 2, 3
- adequate planning and lopinavir ritonavir: 1
- adjust analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjust analysis and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date